Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals, Inc. reported that it received a Paragraph IV Certification Notice Letter from Sandoz, Inc., which has filed an Abbreviated New Drug Application with the U.S. FDA seeking approval to market a generic version of Mirum’s drug Livmarli (maralixibat). Sandoz alleges that five Livmarli patents listed in the FDA Orange Book are invalid, unenforceable, or not infringed by its proposed generic. Under U.S. law, Mirum may file a patent infringement lawsuit within 45 days of receiving the notice, which would trigger an automatic 30-month stay on final FDA approval of the ANDA. Mirum states that it plans to vigorously enforce its intellectual property, promptly sue Sandoz and any other ANDA filers, and seek a permanent injunction against generic versions that would infringe its patents.
Mirum Pharmaceuticals (MIRM) reported strong Q3 2025 results. Product sales, net reached $133,010 thousand, up from $90,302 thousand a year ago, driven by Livmarli at $92,235 thousand and Bile Acid Medicines at $40,775 thousand. The company posted net income of $2,905 thousand, or $0.05 diluted EPS, versus a loss last year.
Cash and cash equivalents were $282,021 thousand, with unrestricted cash, cash equivalents and investments of $378.0 million as of September 30, 2025. Year‑to‑date operating cash flow was $49,760 thousand. Stockholders’ equity rose to $292,046 thousand from $225,640 thousand at year‑end. Principal on the 4.00% Convertible Senior Notes due 2029 was $316,233 thousand; the notes met conversion conditions in Q3 and Q4 2025, and conversions to date were not material. Total U.S. product sales were $103,713 thousand, with $29,297 thousand from the rest of the world. Common shares outstanding were 51,393,574 as of October 31, 2025.
Mirum Pharmaceuticals, Inc. furnished a press release that provides a corporate update and announces its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into this report. The company also specifies that this information is being furnished, not filed, which limits how it is treated under securities laws and how it may be incorporated into other regulatory documents.
Mirum Pharmaceuticals reported a Form 144 notice showing a proposed sale of 17,000 common shares to be executed through Morgan Stanley Smith Barney on 09/11/2025. The filing lists an aggregate market value of $1,264,917.30 for the shares against 50,237,647 shares outstanding. The shares were acquired and are being sold on 09/11/2025 as the result of a stock option exercise with payment in cash. The filer certifies they are not aware of undisclosed material adverse information about the issuer. The notice reports no other sales in the past three months.
Insider transactions by a company director: Mirum Pharmaceuticals director Saira Ramasastry exercised a stock option and sold the resulting shares on 09/08/2025. The reporting shows an exercise (code M) of 17,000 shares at a conversion/exercise price of $23.51, followed the same day by a sale (code S) of 17,000 common shares at a weighted average sale price of $77.042178 (range: $76.835–$77.29). The derivative disclosure notes the option is fully vested. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Mirum Pharmaceuticals is registering 1,500,000 additional shares of common stock under its 2020 Inducement Plan, bringing the plan total to 5,500,000 shares. The additional shares were approved by the Compensation Committee and are the same class as shares previously registered under prior Form S-8 filings. The Registration Statement incorporates by reference specified prior annual, quarterly and current reports filed with the SEC and the companys Form 8-A description of common stock, and states subsequently filed reports under Sections 13, 14 or 15(d) will also be incorporated by reference.
Mirum Pharmaceuticals (MIRM) filed a Form 144 notifying a proposed sale of securities. The filing shows 17,000 common shares to be sold through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $1,309,715.70 and total shares outstanding listed as 50,237,647. The securities were acquired and are proposed to be sold on 09/08/2025 via a stock option exercise, with cash payment recorded. The filer reports no securities sold in the past three months for the account. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
Frazier-affiliated investment vehicles amended a Schedule 13D for Mirum Pharmaceuticals (MIRM) to correct prior attributions and restate holdings. The filing shows Frazier Life Sciences IX, L.P. directly holds 3,566,912 shares (about 7.1% of 50,237,647 outstanding shares as of August 1, 2025). Related Frazier funds and vehicles report additional direct holdings: Frazier Life Sciences X (168,308 shares), Frazier Life Sciences XI (544,954 shares), Frazier Life Sciences Public Fund (1,574,374 shares) and Frazier Life Sciences Public Overage Fund (940,573 shares). Reporting clarifies that certain investment committee members are not attributed beneficial ownership and corrects prior overstatements. Individual reporting persons James N. Topper and Patrick J. Heron are shown with aggregate beneficial ownership positions reflecting the fund holdings and, for Heron, options that affect percentage calculations.
Janus Henderson Group plc reports beneficial ownership of Mirum Pharmaceuticals common stock totaling 5,236,277 shares, representing approximately 10.6% of the outstanding class. The filing shows the reporting entity holds no sole voting or dispositive power and reports shared voting and dispositive power over the stake. A listed subsidiary, JHIUS, is reported as beneficial owner of 5,140,740 shares (about 10.4%) with shared voting and dispositive authority. The filer certifies these securities are held in the ordinary course of business and not to change control of the issuer.
Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals, sold 8,000 shares on 08/11/2025 at a weighted average price of $65.50 (range $65.31–$66.00) and on 08/12/2025 exercised employee stock options to acquire 2,954 shares at an exercise price of $26.49 per share. After these transactions the filing reports beneficial ownership of 31,190 shares. The filing notes 290 shares were acquired under the company Employee Stock Purchase Plan on May 10, 2025. The related option grant vests with one quarter after January 23, 2024 and the remainder in 36 equal monthly installments, and the form was signed by an attorney-in-fact.